Source link : https://www.newshealth.biz/health-news/no-hiv-infections-after-twice-a-year-prep/
Lenacapavir, a twice-yearly injectable HIV-1 capsid inhibitor, has shown 100% efficacy in preventing HIV in women at a high risk for infection, according to an interim analysis of the phase 3 PURPOSE 1 trial. The results were so promising that the independent data monitoring committee recommended that Gilead Sciences stop the blinded phase of the […]
Author : News Health
Publish date : 2024-07-05 11:23:32
Copyright for syndicated content belongs to the linked Source.
Categories